Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less ...

Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

A trial of Sanofi’s new eczema drug has disappointed investors hoping for a replacement for its blockbuster Dupixent, sending the French pharma group’s shares down more than 9 per cent on Thursday.

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

Amlitelimab showed efficacy in skin clearance compared to a placebo, but the results underwhelmed investors.

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Amgen (AMGN) stock in focus as the company and Kyowa Kirin (KYKOF) report Phase 3 data showing their atopic dermatitis drug, ...

First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough ...

New York City-based Pfizer earned approval from the Food and Drug Administration for its topical drug Eucrisa, reports Reuters. Eucrisa, known under the generic name crisaborole, is intended to treat ...